BRIEF-Bristol Myers Squibb Receives Approval From The European Commission To Expand Use Of Car T Cell Therapy Breyanzi For Relapsed Or Refractory Follicular Lymphoma

Reuters
14 Mar
BRIEF-Bristol Myers Squibb Receives Approval From The European Commission To Expand Use Of Car T Cell Therapy Breyanzi For Relapsed Or Refractory Follicular Lymphoma

March 14 (Reuters) - Bristol-Myers Squibb Co BMY.N:

  • BRISTOL MYERS SQUIBB RECEIVES APPROVAL FROM THE EUROPEAN COMMISSION TO EXPAND USE OF CAR T CELL THERAPY BREYANZI FOR RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

Source text: ID:nBw9q6jqsa

Further company coverage: BMY.N

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10